- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT00021632
Effects of Ribavirin on Zidovudine or Stavudine
Pharmacokinetic Evaluation of the Effects of Ribavirin (RBV) on Zidovudine (ZDV) or Stavudine (d4T) Triphosphate (TP) Formation
The purpose of this study is to see how treatment of hepatitis C (HCV) patients with ribavirin (RBV) affects the anti-HIV drugs stavudine (d4T) or zidovudine (ZDV).
Studies have shown that RBV may interfere with the action of ZDV and d4T. There is little information about the way these drugs interact in the body. This study will examine how the drug RBV affects levels of ZDV or d4T in patients who are currently on stable anti-HIV therapy.
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
RBV, a nucleoside analogue, is used for the treatment of hepatitis C virus (HCV) in alliance with interferon-alfa 2a/2b in patients with HIV-1. The mechanism of action of RBV has led to in vitro studies examining the agonism/antagonism in efficacy occurring when used in combination with nucleoside reverse transcriptase inhibitors (NRTIs). The primary objective of the pharmacology component of this current study will be the evaluation of the effect of RBV on the intracellular activation of ZDV or d4T owing to the reported antagonism observed in vitro.
Pharmacokinetic (PK) evaluations for plasma ZDV or d4T and intracellular ZDV or d4T and measurements of their triphosphate anabolites are performed before initial RBV dosing (within 2 weeks of visit) and 8 weeks after RBV administration. Thymidine triphosphate (TTP) concentrations also are quantitated to permit estimation of the ratio of active drug to endogenous triphosphate concentrations.
For entry, prior to RBV dosing, blood samples are collected within 2 hours prior to the ZDV or d4T dose and then at Hours 1, 4, and 8 post dosing. Following the entry PK blood draws, patients initiate RBV treatment within 2 weeks of the first PK study day.
For the Week 8 evaluation (measured as 8 weeks following initiation of RBV), blood samples are collected prior to the ZDV or d4T dose and then at Hours 1, 4, and 8 post dosing.
Tipo di studio
Iscrizione
Contatti e Sedi
Luoghi di studio
-
-
California
-
Los Angeles, California, Stati Uniti, 90095
- UCLA CARE Ctr
-
Stanford, California, Stati Uniti, 943055107
- San Mateo AIDS Program / Stanford Univ
-
Stanford, California, Stati Uniti, 943055107
- Stanford Univ Med Ctr
-
Stanford, California, Stati Uniti, 94305
- Willow Clinic / Stanford Univ
-
-
Maryland
-
Baltimore, Maryland, Stati Uniti, 21287
- Johns Hopkins Hosp
-
-
Ohio
-
Cleveland, Ohio, Stati Uniti, 44109-1998
- MetroHealth Medical Center
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria
Patients may be eligible for this study if they:
- Are at least 13 years of age.
- Have written consent from parent or guardian if under 18 years of age.
- Have HIV infection.
- Have been receiving ZDV or d4T for at least 4 weeks prior to study entry.
- Are planning to receive RBV-containing hepatitis treatment through their doctor or through coenrollment in another ACTG protocol within 2 weeks following entry into the study.
- Have not received RBV for at least 6 months prior to study entry if they were previously treated with RBV.
- Weigh more than 110 pounds (50 kg).
Exclusion Criteria
Patients will not be eligible for this study if they:
- Are pregnant.
- Use rifampin, rifabutin, pyrazinamide, isoniazid, ganciclovir, or hydroxyurea within 14 days of study entry.
- Abuse alcohol or drugs. Patients in methadone programs may participate.
Piano di studio
Come è strutturato lo studio?
Collaboratori e investigatori
Pubblicazioni e link utili
Studiare le date dei record
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- ACTG A5092s
- AACTG A5092s
- 10919 (Identificatore di registro: DAIDS-ES)
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su Infezioni da HIV
-
University of MinnesotaRitiratoInfezioni da HIV | HIV/AIDS | HIV | AIDS | Problema di Aids/Hiv | AIDS e infezioniStati Uniti
-
Erasmus Medical CenterNon ancora reclutamentoInfezioni da HIV | HIV | Infezione da HIV-1 | Infezione da HIV IOlanda
-
Helios SaludViiV HealthcareSconosciutoHIV | Infezione da HIV-1Argentina
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement; Centre Pasteur du Cameroun e altri collaboratoriSconosciutoHIV | Bambini non infetti da HIV | Bambini esposti all'HIVCamerun
-
University of MinnesotaCompletatoInfezioni da HIV | HIV | ImmunodeficienzaStati Uniti
-
Allegheny Singer Research Institute (also known...Attivo, non reclutanteInfezioni da HIV | Infezione da HIV-1 | Infezione da HIV IStati Uniti
-
University of California, DavisCompletato
-
University of ChicagoUniversity of Athens; National Development and Research Institutes, Inc.Completato
-
University of ZimbabweCompletato
-
Boston Children's HospitalNational Institute on Minority Health and Health Disparities (NIMHD)Completato